Mettis Global News
Mettis Global News
Mettis Global News
Mettis Global News

MPS Preview: High for Longer

GSK suspends all ranitidine containing products in the market

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

September 26, 2019 (MLN): GlaxoSmithKline Pakistan Limited (GSK), has announced to suspend the release, distribution and supply of all dose forms of ranitidine hydrochloride products to all markets including Pakistan, after being contacted by regulatory authorities regrading the detection of genotoxic nitrosamine NDMA in ranitidine products.

The decision was taken as a precautionary action pending the outcome of ongoing tests and investigations, revealed an official notification sent by the company to the exchange.

As per the notification, GSK Pakistan has proactively informed the Drug Regulatory Authority of Pakistan (DRAP) about the above-mentioned decision. Subsequently, the DRAP has advised Pharma companies to recall all ranitidine containing products in the market till further orders.

Copyright Mettis Link News

Posted on: 2019-09-26T11:57:00+05:00

30178